Skip to main content

Focus on less invasive treatments for heavy menstrual bleeding

Women’s Health - Heavy Menstrual BleedingOn 13 June 2024 the Australian Commission on Safety and Quality in Health Care released national trend data in a new report suggesting that women may be turning from hysterectomy to less invasive treatments for heavy menstrual bleeding, a condition that affects one in four Australian women.

It has also released an updated Heavy Menstrual Bleeding Clinical Care Standard (2024) to ensure that women with this condition can make an informed choice about the most appropriate treatment for their individual situation.

Together these resources aim to improve care for women with heavy menstrual bleeding, which can have a substantial impact on a woman's quality of life.

Hysterectomy is one option for treating heavy menstrual bleeding, but there are a number of associated risks. Less invasive treatments are available, including oral medicines, the hormonal IUD and procedures like endometrial ablation. 

Key findings

The Women’s Health Focus Report found a 20% decrease nationally in the rate of hysterectomy between 2014-15 and 2021-22, and a 10% increase in the rate of the less invasive option of endometrial ablation (2013-16 and 2019-22).* 

However, the data indicate inconsistencies in care across the country. Rates for both procedures were consistently higher in regional areas than in major cities and remote areas. In 2021-22, the hysterectomy rate for First Nations women was 9% higher than for other Australian women.

Use the Report’s interactive maps and graphs to view hospitalisation rates and trends in your state or territory, PHN and local area. If substantial variation exists, investigate whether appropriate care is being delivered in line with the Standard. 

Download the Standard and implementation resources to learn more about best practice care and local improvement opportunities for women with heavy menstrual bleeding.

Read more …Focus on less invasive treatments for heavy menstrual bleeding

Menopausal Hormone Therapy (MHT) patch shortages May 2024

Australia 

Patch Shortages

There are a number of MHTs that are currently unavailable. Please note that the TGA has approved some unregistered products under Section 19A and some substitute doses are currently in supply in Australia.

Pharmacists are encouraged to contact suppliers Medsurge Healthcare Pty Ltd on 1300 788 261 for orders of Estramon and Sandoz on 1800 726 369 for orders of Estradiol Transdermal System.

Oestradiol patches

 

Expected supply due

Alternative supply under Section 19A

Dose

Estradot

Estraderm

Estramon

Estradiol Transdermal System

25 mcg

15 Jun 2024

Available

Available

 

37.5 mcg

20 Sep 2024

 

Available

Available

50 mcg

15 Jun 2024

1 Aug 2024

Available

 Available

75 mcg

15 Jun 2024

1 Aug 2024

Available

Available

100 mcg

15 Jul 2024

1 Aug 2024

Available

Available

Combined patches

Dose

Estalis Sequi

Estalis Conti

50/140

17 June 2024

8 Jun 2024

50/250

15 Jul 2024

3 Aug 2024

All doses of Climara have been deleted from the market and there will be a reduction in supply until supply is exhausted.

The AMS Guide to MHT Doses (Australia only) provides a guideline to approximately equivalent doses of the different MHT/HRT products in Australia.

Read more …Menopausal Hormone Therapy (MHT) patch shortages May 2024